vs
Side-by-side financial comparison of DANA Inc (DAN) and UNITED THERAPEUTICS Corp (UTHR). Click either name above to swap in a different company.
DANA Inc is the larger business by last-quarter revenue ($1.3B vs $790.2M, roughly 1.6× UNITED THERAPEUTICS Corp). UNITED THERAPEUTICS Corp runs the higher net margin — 46.1% vs -3.9%, a 50.0% gap on every dollar of revenue. On growth, UNITED THERAPEUTICS Corp posted the faster year-over-year revenue change (7.4% vs -44.5%). DANA Inc produced more free cash flow last quarter ($345.0M vs $173.3M). Over the past eight quarters, UNITED THERAPEUTICS Corp's revenue compounded faster (8.0% CAGR vs -31.2%).
Dana Incorporated is an American supplier of axles, driveshafts, and electrodynamic, thermal, sealing, and digital equipment for conventional, hybrid, and electric-powered vehicles. The company's products and services are aimed at the light vehicle and commercial vehicle equipment markets. Founded in 1904 and based in Maumee, Ohio, the company employs nearly 28,000 people in 33 countries. In 2022, Dana generated sales of $10.2 billion. The company is included in the Fortune 500.
United Therapeutics Corporation is an American biotechnology company that develops pharmaceuticals and technologies related to organ transplantation, including xenotransplantation. Many of the company's products are focused towards lung disease and organ manufacturing. United Therapeutics is co-headquartered in Silver Spring, Maryland and Research Triangle Park, North Carolina, with additional facilities in Magog and Bromont, Quebec; Melbourne and Jacksonville, Florida; Blacksburg, Virginia; ...
DAN vs UTHR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $790.2M |
| Net Profit | $-50.0M | $364.3M |
| Gross Margin | 6.0% | 86.9% |
| Operating Margin | -0.2% | 45.1% |
| Net Margin | -3.9% | 46.1% |
| Revenue YoY | -44.5% | 7.4% |
| Net Profit YoY | 37.5% | 20.9% |
| EPS (diluted) | $-0.36 | $7.66 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3B | $790.2M | ||
| Q3 25 | $1.9B | $799.5M | ||
| Q2 25 | $1.9B | $798.6M | ||
| Q1 25 | $2.4B | $794.4M | ||
| Q4 24 | $2.3B | $735.9M | ||
| Q3 24 | $2.5B | $748.9M | ||
| Q2 24 | $2.7B | $714.9M | ||
| Q1 24 | $2.7B | $677.7M |
| Q4 25 | $-50.0M | $364.3M | ||
| Q3 25 | $83.0M | $338.7M | ||
| Q2 25 | $27.0M | $309.5M | ||
| Q1 25 | $25.0M | $322.2M | ||
| Q4 24 | $-80.0M | $301.3M | ||
| Q3 24 | $4.0M | $309.1M | ||
| Q2 24 | $16.0M | $278.1M | ||
| Q1 24 | $3.0M | $306.6M |
| Q4 25 | 6.0% | 86.9% | ||
| Q3 25 | 8.7% | 87.4% | ||
| Q2 25 | 7.1% | 89.0% | ||
| Q1 25 | 9.4% | 88.4% | ||
| Q4 24 | 5.7% | 89.7% | ||
| Q3 24 | 9.9% | 88.9% | ||
| Q2 24 | 9.3% | 89.1% | ||
| Q1 24 | 8.9% | 89.2% |
| Q4 25 | -0.2% | 45.1% | ||
| Q3 25 | 2.8% | 48.6% | ||
| Q2 25 | 0.8% | 45.6% | ||
| Q1 25 | 3.1% | 48.2% | ||
| Q4 24 | -1.5% | 48.6% | ||
| Q3 24 | 3.6% | 45.8% | ||
| Q2 24 | 3.8% | 44.7% | ||
| Q1 24 | 2.6% | 52.6% |
| Q4 25 | -3.9% | 46.1% | ||
| Q3 25 | 4.3% | 42.4% | ||
| Q2 25 | 1.4% | 38.8% | ||
| Q1 25 | 1.1% | 40.6% | ||
| Q4 24 | -3.4% | 40.9% | ||
| Q3 24 | 0.2% | 41.3% | ||
| Q2 24 | 0.6% | 38.9% | ||
| Q1 24 | 0.1% | 45.2% |
| Q4 25 | $-0.36 | $7.66 | ||
| Q3 25 | $0.64 | $7.16 | ||
| Q2 25 | $0.19 | $6.41 | ||
| Q1 25 | $0.17 | $6.63 | ||
| Q4 24 | $-0.55 | $6.23 | ||
| Q3 24 | $0.03 | $6.39 | ||
| Q2 24 | $0.11 | $5.85 | ||
| Q1 24 | $0.02 | $6.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $469.0M | $2.9B |
| Total DebtLower is stronger | $2.6B | — |
| Stockholders' EquityBook value | $840.0M | $7.1B |
| Total Assets | $7.8B | $7.9B |
| Debt / EquityLower = less leverage | 3.05× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $469.0M | $2.9B | ||
| Q3 25 | $414.0M | $2.8B | ||
| Q2 25 | $486.0M | $3.0B | ||
| Q1 25 | $507.0M | $3.3B | ||
| Q4 24 | $494.0M | $3.3B | ||
| Q3 24 | $419.0M | $3.3B | ||
| Q2 24 | $419.0M | $3.0B | ||
| Q1 24 | $351.0M | $2.7B |
| Q4 25 | $2.6B | — | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.6B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.6B | — |
| Q4 25 | $840.0M | $7.1B | ||
| Q3 25 | $1.1B | $6.6B | ||
| Q2 25 | $1.2B | $7.2B | ||
| Q1 25 | $1.4B | $6.8B | ||
| Q4 24 | $1.3B | $6.4B | ||
| Q3 24 | $1.5B | $6.1B | ||
| Q2 24 | $1.5B | $5.7B | ||
| Q1 24 | $1.5B | $5.3B |
| Q4 25 | $7.8B | $7.9B | ||
| Q3 25 | $8.1B | $7.4B | ||
| Q2 25 | $8.1B | $7.9B | ||
| Q1 25 | $7.8B | $7.7B | ||
| Q4 24 | $7.5B | $7.4B | ||
| Q3 24 | $7.9B | $7.1B | ||
| Q2 24 | $7.8B | $6.7B | ||
| Q1 24 | $7.9B | $6.5B |
| Q4 25 | 3.05× | — | ||
| Q3 25 | 2.35× | — | ||
| Q2 25 | 2.13× | — | ||
| Q1 25 | 1.76× | — | ||
| Q4 24 | 1.79× | — | ||
| Q3 24 | 1.65× | — | ||
| Q2 24 | 1.62× | — | ||
| Q1 24 | 1.68× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $406.0M | $346.2M |
| Free Cash FlowOCF − Capex | $345.0M | $173.3M |
| FCF MarginFCF / Revenue | 26.6% | 21.9% |
| Capex IntensityCapex / Revenue | 4.7% | 21.9% |
| Cash ConversionOCF / Net Profit | — | 0.95× |
| TTM Free Cash FlowTrailing 4 quarters | $298.0M | $1.0B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $406.0M | $346.2M | ||
| Q3 25 | $111.0M | $562.1M | ||
| Q2 25 | $32.0M | $191.7M | ||
| Q1 25 | $-37.0M | $461.2M | ||
| Q4 24 | $302.0M | $341.2M | ||
| Q3 24 | $35.0M | $377.2M | ||
| Q2 24 | $215.0M | $232.2M | ||
| Q1 24 | $-102.0M | $376.5M |
| Q4 25 | $345.0M | $173.3M | ||
| Q3 25 | $62.0M | $351.6M | ||
| Q2 25 | $3.0M | $129.5M | ||
| Q1 25 | $-112.0M | $386.3M | ||
| Q4 24 | $149.0M | $254.5M | ||
| Q3 24 | $-11.0M | $300.7M | ||
| Q2 24 | $104.0M | $187.1M | ||
| Q1 24 | $-172.0M | $338.3M |
| Q4 25 | 26.6% | 21.9% | ||
| Q3 25 | 3.2% | 44.0% | ||
| Q2 25 | 0.2% | 16.2% | ||
| Q1 25 | -4.8% | 48.6% | ||
| Q4 24 | 6.4% | 34.6% | ||
| Q3 24 | -0.4% | 40.2% | ||
| Q2 24 | 3.8% | 26.2% | ||
| Q1 24 | -6.3% | 49.9% |
| Q4 25 | 4.7% | 21.9% | ||
| Q3 25 | 2.6% | 26.3% | ||
| Q2 25 | 1.5% | 7.8% | ||
| Q1 25 | 3.2% | 9.4% | ||
| Q4 24 | 6.6% | 11.8% | ||
| Q3 24 | 1.9% | 10.2% | ||
| Q2 24 | 4.1% | 6.3% | ||
| Q1 24 | 2.6% | 5.6% |
| Q4 25 | — | 0.95× | ||
| Q3 25 | 1.34× | 1.66× | ||
| Q2 25 | 1.19× | 0.62× | ||
| Q1 25 | -1.48× | 1.43× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | 8.75× | 1.22× | ||
| Q2 24 | 13.44× | 0.83× | ||
| Q1 24 | -34.00× | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DAN
| Light Vehicle Segment | $912.0M | 70% |
| Commercial Vehicle Segment | $218.0M | 17% |
| Other | $166.0M | 13% |
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
